Home > Protocol Summaries: Compounds > SB656933 Protocol Summaries: SB656933 GSKStudy ID Phase Title Status 110399 phase 2 A Randomized, Double Blind, Parallel Group, Placebo Controlled 28 Day Study to Investigate the Safety, Tolerability and Pharmacodynamics of SB-656933 in Patients with Cystic Fibrosis. Completed CF2110398 phase 1 An open label dose ascending, single dose study to investigate the pharmacokinetics of SB-656933 in subjects with cystic fibrosis. Completed CR2100597 Phase 1 A randomised, double-blind, placebo controlled, 3-way crossover study to evaluate the pharmacodynamics of SB-656933-AAA following single doses in healthy adult subjects undergoing ozone challenge. Completed CR2100609 Phase 1 See Detailed Description Completed CR2111256 Phase 1 A randomized, double-blind, placebo controlled study to evaluate the safety, tolerability, and pharmacokinetics of SB-656933 following 14 days repeat dosing in healthy male smokers. Completed CUC111342 phase 2 An open label, 7-day repeat dose study to evaluate the pharmacodynamics of SB-656933-AAA in patients with Ulcerative Colitis. Terminated
